Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Inks Early-Stage Collaboration Related to miRNA Therapies

Premium

MDRNA said this week that it has signed a new early collaborative effort with an undisclosed company focused on microRNA-directed oncology therapies.

According to the company, the arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models." Additional terms of the deal were not disclosed.

The DiLA2 technology relates to synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.